Correvio Pharma Corp.

CORV

CA22026V1058

Pharmaceuticals

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		-5.08%	+3.70%

2020	Mark Corrigan Departs as CEO from Correvio Pharma Corp	CI
2020	Justin Renz, CFO Departs from Correvio Pharma Corp	CI

Correvio Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2018

March 13, 2019 at 04:30 pm IST

Correvio Pharma Corp. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced total revenue was USD 28.674 million compared to USD 24.008 million a year ago. Operating income was USD 26.341 million compared to USD 22.979 million a year ago. Net loss was USD 16.579 million compared to USD 29.811 million a year ago. Basic loss per share was USD 0.47 compared to USD 0.9 a year ago.

Latest news about Correvio Pharma Corp.

Mark Corrigan Departs as CEO from Correvio Pharma Corp	27/20/27	CI
Justin Renz, CFO Departs from Correvio Pharma Corp	27/20/27	CI
Correvio Pharma Corp. Announces Management Changes	27/20/27	CI
Mercury Pharma Group Limited completed the acquisition of Correvio Pharma Corp..	27/20/27	CI
Transcript : Correvio Pharma Corp. - Shareholder/Analyst Call	15/20/15
Correvio Pharma Corp. Postpones Announcement of Financial Statements for the First Quarter Ended March 31, 2020	04/20/04	CI
Correvio Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	30/20/30	CI
Correvio Pharma Corp. Auditor Raises 'Going Concern' Doubt	30/20/30	CI
Mercury Pharma Group Limited entered into an arrangement agreement to acquire Correvio Pharma Corp. for $21.3 million.	16/20/16	CI
Correvio Pharma Corp. Receives Complete Response Letter from U.S. FDA for Brinavess and Provides Update on Recent Events	24/19/24	CI
Correvio Pharma to explore sale after FDA panel setback; shares hit record low	12/19/12	RE
Correvio Pharma Corp Announces Outcome of FDA Advisory Committee Meeting Review of Brinavess for the Treatment of Recent Onset Atrial Fibrillation	11/19/11	CI
Correvio Announces Presentation of New Brinavess™ Spectrum Data	18/19/18	CI
Transcript : Correvio Pharma Corp., Q3 2019 Earnings Call, Nov 14, 2019	14/19/14
Correvio Pharma Corp. Reiterates Revenue Guidance for the Full-Year 2019	14/19/14	CI
Correvio Pharma Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2019	14/19/14	CI
Certain Common Shares of Correvio Pharma Corp. are subject to a Lock-Up Agreement Ending on 16-OCT-2019.	16/19/16	CI
Certain Stock Options of Correvio Pharma Corp. are subject to a Lock-Up Agreement Ending on 16-OCT-2019.	16/19/16	CI
Correvio Pharma Corp. Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application	12/19/12	CI
Correvio Pharma Corp. Announces Presentation of Brinavess Spectrum Data at the European Society of Cardiology 2019 Congress	03/19/03	CI
Transcript : Correvio Pharma Corp., Q2 2019 Earnings Call, Aug 14, 2019	14/19/14
Correvio Pharma Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/19/14	CI
Correvio Pharma Corp. Announces Brinavess Spectrum Data to Present At the European Society of Cardiology 2019 Congress	12/19/12	CI
U.S. Food and Drug Administration Accepts Correvio Pharma Corp.'s Resubmitted New Drug Application for Brinavess (Vernakalant)	25/19/25	CI
Correvio Pharma Corp. Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation	24/19/24	CI

Chart Correvio Pharma Corp.

Duration

Period

More charts

Company Profile

Correvio Pharma Corp is a Canada-based company, which is a specialty pharmaceutical company. The Company focused on providing acute services. It's portfolio brands includes: Xydalba (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. Its products include Trevyent, a drug-device combination that is designed to deliver treprostinil, the treatment for pulmonary arterial hypertension.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
CORREVIO PHARMA CORP.	+3.70%	2.76Cr
KYOWA KIRIN CO. LTD.	+8.35%	872.08Cr
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	478.98Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+47.36%	462.18Cr
YUHAN CORPORATION	+1.74%	382.39Cr
INDIVIOR PLC	+14.51%	233.24Cr
BETTA PHARMACEUTICALS CO., LTD.	-26.23%	219.75Cr
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.63%	209.63Cr
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-34.87%	203.91Cr
VELOXIS PHARMACEUTICALS A/S	-0.50%	164.41Cr

Specialty & Advanced Pharmaceuticals